NLS Pharmaceutics (NLSP) has released an update.
NLS Pharmaceutics Ltd. has announced promising preclinical results for its novel Parkinson’s Disease treatments, revealing that its compounds, particularly AEX-23, show potential for improving neuronal health and connectivity. The company’s research demonstrated positive effects on neurite outgrowth and decreased alpha-synuclein aggregation, suggesting possible neuroprotective benefits. NLS Pharmaceutics plans to further this research by developing two new compounds, AEX-230 and AEX-231, aimed at enhancing treatment strategies for neurodegenerative disorders.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
